Winthrop P. Rockefeller Cancer Institute
January 19, 2024
Arkansan Sees Advanced Cancer Disappear with Experimental Drug Offered at UAMS Winthrop P. Rockefeller Cancer Institute
A Little Rock man with resistant kidney cancer who underwent experimental immunotherapy in Phase 1 Clinical Trials at the University of Arkansas for Medical Sciences (UAMS) Winthrop P. Rockefeller Cancer Institute has experienced a complete remission.
January 18, 2024
UAMS Winthrop P. Rockefeller Cancer Institute to Hold Health Fair in Huntsville on Feb. 9
The University of Arkansas for Medical Sciences (UAMS) Winthrop P. Rockefeller Cancer Institute will host a free public health fair at the Madison County Public Library in Huntsville on Feb. 9. The event will run from 10 a.m. to 1 p.m. at the library, located at 827 N. College St. Patient navigators from the UAMS…
December 15, 2023
Behind the Scenes
Yan Cheng, Ph.D. Yan Cheng, Ph.D., is an instructor for the UAMS Winthrop P. Rockefeller Cancer Institute’s Myeloma Center. Cheng, who joined the Myeloma Center team in 2021, conducts translational research, including identifying the biology of multiple myeloma risk genes. Her research focuses on unravelling the mechanisms of resistance to therapy to help develop new…
Publications
Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level Blood Advances November 2022 Primary author: Carolina Schinke, M.D. Multiple myeloma (MM) is preceded by precursor stages including MGUS and smoldering myeloma. It is thought that the acquisition of mutations in the myeloma cells is responsible for disease progression through these…
Nurse Passionate About Success, Impact of UAMS Myeloma Center
Heather Brown, APRN, a nurse practitioner for the University of Arkansas for Medical Sciences (UAMS) Winthrop P. Rockefeller Cancer Institute’s Myeloma Center, appreciates the opportunity to serve the patients. A 2001 graduate of the UAMS College of Nursing, Brown quickly learned about myeloma as the center opened shortly after she was hired by the institute….
Intake Team Serves as Source of Comfort for Myeloma Center Patients
For new patients of the UAMS Myeloma Center, the intake process provides their first impression of the support they’ll receive during a difficult period of their lives. “It’s important that we help them get established and make sure they’re comfortable coming here,” said Christy Bunting, an intake coordinator in the Myeloma Center. “We want them…
UAMS Myeloma Researcher Sees‘ Impressive’ Results in Clinical Trials of Bispecific Antibody Treatments
Many patients at the UAMS Myeloma Center have relapsed refractory myeloma, meaning they have nearly run out of effective treatment options. Fortunately, the center has talented clinical researchers like Carolina Schinke, M.D., with access to the latest medications, including promising study drugs. Schinke is leading a clinical trial at UAMS of a promising new bispecific…
December 14, 2023
UAMS Researcher Takes Aim at Drug-Resistant Myeloma
UAMS Myeloma Center researcher Fenghuang (Frank) Zhan, M.D., Ph.D., has spent his career in search of clues to help fight drug-resistant myeloma. His findings recently led him to establish a translational research project to beat drug-resistant myeloma for his 11-member myeloma research team, based at the UAMS Winthrop P. Rockefeller Cancer Institute. While the five-year…
New Immune Therapies Provide Promising Advances in Myeloma Care
By Frits van Rhee, MD, Ph.D. Since the late 1990s, 16 drugs have been approved for the treatment of multiple myeloma, including proteasome inhibitors, such as bortezomib and carfilzomib, and the immunomodulatory class of agents comprising thalidomide, lenalidomide and pomalidomide. Immune therapy with the antibody daratumumab was first approved in 2015. These three classes of…
Expanding the Field: Clinical Trials Diversity Benefits Myeloma Research
Clinical trials have long been an established part of medical research. The University of Arkansas for Medical Sciences (UAMS) Myeloma Center and the Clinical Trials Office work together to create a more diverse pool of clinical trial participants in the continuing research of multiple myeloma. Samer Al Hadidi, M.D., is a driving force in this…
Previous page Next page